Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Natal DHA is a prescription-strength prenatal and postnatal multivitamin and mineral supplement that includes docosahexaenoic acid (DHA), an omega-3 fatty acid. Developed and marketed by Trigen Laboratory, it is designed to provide comprehensive nutritional support for women during pregnancy and the postpartum period, including lactation. The formulation typically contains essential nutrients such as folic acid, which is critical for DNA synthesis and the prevention of neural tube defects; iron, which supports increased maternal blood volume and fetal oxygenation; and DHA, which is a primary structural component of the fetal brain and retina. As a prescription product, it is formulated to meet specific therapeutic levels of vitamins and minerals that may exceed standard over-the-counter dietary supplement concentrations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Natal DHA.